BSF 208791
Latest Information Update: 24 Jan 2013
At a glance
- Originator Abbott GmbH & Co. KG
- Class Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 12 Sep 2006 Discontinued - Phase-I for Thrombosis in Europe (unspecified route)
- 13 Mar 2001 BASF's pharmaceutical business has been acquired by Abbott Laboratories
- 07 Feb 2001 New profile